Comparative Pharmacology
Head-to-head clinical analysis: CECLOR versus CEPHALOTHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR versus CEPHALOTHIN.
CECLOR vs CEPHALOTHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible organisms.
Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking peptidoglycan cross-linking. It has activity against gram-positive cocci (e.g., Staphylococcus aureus, Streptococcus pyogenes) and some gram-negative bacilli (e.g., Escherichia coli, Klebsiella pneumoniae).
250 mg orally every 8 hours; for severe infections, 500 mg orally every 8 hours.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.9 hours in adults with normal renal function. Prolonged to 2-3 hours in end-stage renal disease. Half-life does not increase significantly with hepatic impairment.
0.5-1 hour in patients with normal renal function; prolonged to 2-8 hours in moderate renal impairment (CrCl 30-50 mL/min); up to 20-30 hours in end-stage renal disease; due to rapid elimination, frequent dosing (q4-6h) is required for continuous bactericidal levels.
Primarily renal: 80-90% of unchanged drug excreted by glomerular filtration and tubular secretion within 8 hours. Biliary excretion accounts for <5%; fecal elimination negligible.
Primarily renal (60-90% unchanged) via tubular secretion and glomerular filtration; minor biliary excretion (less than 5%); hepatic metabolism to desacetylcephalothin (active but less potent) accounts for about 20-30% of dose; fecal elimination negligible.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic